Exclusive Summary

• Strong rigid global demand: As a WHO Essential Medicine driven by over 300 million surgeries globally per year, it guarantees high and stable institutional procurement volumes.
• Gold standard clinical status: Characterized by rapid onset and no airway irritation, it remains the absolute first-line choice for the induction and maintenance of general anesthesia, notably in pediatrics.
• Significant cost and margin advantages: Backed by China's integrated supply chain, its cost is remarkably lower than originators and Western generic peers, ensuring ample profit margins and strong tender competitiveness for overseas distributors.
• Seamless clinical replacement: The standard 250ml packaging is highly compatible with mainstream anesthetic vaporizers worldwide, backed by comprehensive registration dossiers to minimize entry barriers.